This Week in Pediatric Oncology

TWiPO #53 ~ Interview with Linda McAllister-Lucas

On today's podcast TWiPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-hosts, Dr. Nilay Shah (Nationwide Children’s Hospital) and Dr. Robyn Dennis (Nationwide Children’s Hospital) Interview Dr. Linda McAllister-Lucas (Chief of Service, Hematology/Oncology of Children's Hospital of Pittsburgh, Associate Professor of Pediatrics, University of Pittsburgh School of Medicine. In their discussion Dr. McAllister-Lucas talks about her research on MALT1 Lymphoma and how this research could advance the field of oncology 

TWIPO #52 ~ Interview with Dr. James Geller

On this TWiPO episode hosts, Dr. Timothy Cripe and Dr. Nilay Shah (Nationwide Children’s Hospital) interview Dr. James Geller (Medical Director at Kidney and Liver Tumors Program, Co-Medical Director at Retinoblastoma Program, Associate Director at Global Cancer Programs, Associate Professor at UC Department of Pediatrics.) Dr. James Geller was one of the original TWiPO members back in 2010. Today Dr. Geller talks about the battle to get access to potential drugs (Ex. Lorvotuzumab [IMGN901]) that can be beneficial to treating pediatric cancers.

TWIPO #51 ~ Interview with Dr. Gregory Armstrong

This week
in pediatric oncology TWiPO hosts Dr. Timothy Cripe, Robyn Dennis, MD, Dr.
Nilay Shah interview Dr. Gregory Armstrong (Associate Professor in  the
Department of pediatrics at the University of Tennessee health science center,
Associate member of in the department of epidemiology in cancer control in
Saint Jude's Children's Research Hospital, Director of CNS tumor after
completion of therapy clinic at Saint Jude). Dr. Armstrong and hosts discuss
the Childhood Cancer Survival Study (CCSS) and the advancements we have made in
the field of oncology. Along with problems that they are working to solve.

TWIPO #50 ~ Interview With Dr. Jonathan Finlay

In this most recent TWiPO podcast hosted by Dr. Timothy Cripe (Nationwide Children’s Hospital), he interviews Dr. Jonathan Finlay (Program Director of Neuro-Oncology at Nationwide Children’s Hospital) about sparked in research interest in brain tumors. One of Dr. Finlay’s mentors, helped launch a new treatment, which was able to rescue a proportion of newly diagnosed children who failed conventional chemotherapy, radiation, and surgery. That novel treatment is now a growing method of treating medulloblastoma.

TWIPO #49 ~ Interview With Dr. Robin Norris

TWiPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and TWiPO co-host Dr. Nilay Shah (Nationwide Children’s Hospital) interview Robin Norris, MD, who is a pediatric oncologist and the Director of the Pediatric Developmental Therapeutics Program, Division of Pediatric Hematology and Oncology, at University Hospitals Rainbow Babies & Children's Hospital. Dr. Norris discusses the struggles that adolescents and young adult with cancer face and discusses her involvement in creating an antibody against TEM-1 in order to stop the metastasis of tumors.

TWIPO #48 ~ Interview With Dr. Michael D. Hogarty

TWiPO host Dr. Nilay Shah (Nationwide Children’s Hospital) interviews Dr. Michael D. Hogarty, MD, an attending physician in the Division of Oncology at The Children's Hospital of Philadelphia. Dr. Hogarty recalls his efforts in finding a new way of tackling neuroblastoma by sending 17,000 tumor samples around the world. In this short interview, he discusses his current work in the lab, which involves testing the MYC gene found in children with high-risk neuroblastoma.

TWIPO #47 ~ Interview With Dr. Hiro Shimada

TWiPo co-hosts Dr. Keri Stretby
(Nationwide Children’s Hospital) and
Dr. Nilay Shah (Nationwide Children’s Hospital) interview Hiroyuki Shimada, MD,
PhD, Professor of Clinical Pathology at the Children’s Hospital of Lost
Angeles. Dr. Shimada developed the Shimada neuroblastoma classification system
for neuroblastoma, which was the basis of The International Neuroblastoma
Pathology Classification and now The International Neuroblastoma Risk Group
classification system.

TWIPO #46 ~ ANR Recap: Interview With Dr. Sue Cohn

TWiPO host Dr. Nilay Shah (Nationwide Children’s Hospital) interviewed Susan L. Cohn, MD, a Professor of Pediatrics, Dean of Clinical Research at the University of Chicago at the ANR meeting in Cologne, Germany last year for this episode of This Week in Pediatric Oncology. Dr. Cohn is a highly respected expert in pediatric cancers and blood diseases. She is a leading authority on neuroblastoma and actively researching several aspects of neuroblastoma. Her research has received generous support from the National Institutes of Health/National Cancer Institute and the National Institute of Neurological Disorders and Stroke. Dr. Shaw and Dr. Cohn discuss the future of neuroblastoma research and clinical trial design to create more effective treatment options for children with high-risk disease.

TWIPO #45 ~ Immunotherapy Vaccine for Immunotherapy Vaccine for High-Grade Gliomas

In the most recent episode
of This Week in Pediatric Oncology, co-hosts Dr. Nilay Shah (Nationwide
Children’s Hospital), Dr. Timothy Cripe (Nationwide Children’s Hospital), and
Dr. Lionel Chow (Cincinnati Children’s) discuss the promising results of a
study published in the July issue of Journal
of Clinical Oncology among children with an aggressive brain tumor after receiving
immunotherapy. To see a summary of the study, click here. 

TWIPO #44 ~ ANR Recap: Interview With Professor Michelle Haber and Professor Andrew Pearson

In the most recent
episode of This Week in Pediatric Oncology (TWiPO), the first podcast focusing
on pediatric cancer research, co-hosts Dr. Keri Stretby (Nationwide Children’s
Hospital) and Dr. Nilay
Shah (Nationwide Children’s Hospital), caught up with Professor Michelle
Haber (Executive Director at Children’s Cancer Institute in Australia and Professor Andrew Pearson of
the Cancer Research UK. In this 26-minute podcast, both researchers
discuss the future of neuroblastoma, specifically looking at precision medicine,
the role of gene sequencing and the role of international collaboration to
bring new therapies into the clinic.